Therapeutic Approaches for Duchenne Muscular Dystrophy: Old and New
Overview
Pediatrics
Affiliations
Duchenne muscular dystrophy (DMD) is marked by pathogenic variants in the DMD gene, leading to reduced or absent dystrophin translation, muscle fiber destruction, loss of ambulation, cardiomyopathy, respiratory failure, and eventually death. Disease progression is slowed with use of prednisone or other corticosteroid agents. Gene replacement therapy, which is one of the focus points of this review, has emerged as the most promising potential treatment for DMD, though alternative RNA-based strategies have been employed for patients with specific pathogenic variants. While challenges remain, many of these novel therapeutic approaches hold promise for treating this devastating disease.
Arquillo M, Layug E, Lozada M, Bautista K, Calotes-Castillo L Acta Med Philipp. 2025; 58(21):49-59.
PMID: 39758300 PMC: 11694038. DOI: 10.47895/amp.vi0.7975.
Molecular and Biochemical Therapeutic Strategies for Duchenne Muscular Dystrophy.
Krishna L, Prashant A, Kumar Y, Paneyala S, Patil S, Ramachandra S Neurol Int. 2024; 16(4):731-760.
PMID: 39051216 PMC: 11270304. DOI: 10.3390/neurolint16040055.
Bhattacharyya O, Campoamor N, Armstrong N, Freed M, Schrader R, Crossnohere N Int J Neonatal Screen. 2024; 10(2).
PMID: 38651397 PMC: 11036293. DOI: 10.3390/ijns10020032.
The complex landscape of DMD mutations: moving towards personalized medicine.
Gatto F, Benemei S, Piluso G, Bello L Front Genet. 2024; 15:1360224.
PMID: 38596212 PMC: 11002111. DOI: 10.3389/fgene.2024.1360224.
Shalash R, Levi-Ferber M, Cohen C, Dori A, Brodie C, Henis-Korenblit S Dis Model Mech. 2024; 17(3).
PMID: 38501170 PMC: 11007864. DOI: 10.1242/dmm.050412.